Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink’s CleanCap mRNA capping technology for non-commercial use TriLink BioTechnologies (TriLink ...
TriLink BioTechnologies, a Maravai LifeSciences (MRVI) company and global provider of life science reagents and services, has signed a ...
The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA ...
TriLink BioTechnologies, a Maravai LifeSciences company and provider of life science reagents and services, has partnered ...
TriLink BioTechnologies, a Maravai LifeSciences company (MRVI), has partnered with, Avantor (AVTR) to expand availability of its innovative ...
SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...
This poster explores how a novel polymerase variant provides the tools needed to reduce double-stranded RNA (dsRNA) byproducts during manufacturing, ensuring the tolerability, safety and potency of ...
TriLink BioTechnologies (TriLink), a Maravai LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive license and supply agreement with Aldevron, a ...
SAN DIEGO, February 03, 2025--(BUSINESS WIRE)--TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback